A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production

Table 1 Profiles of patients with TAK and healthy controls

	Risk group (n = 31)	Non-risk group (n = 13)	Healthy controls (n = 19)	P value
Age (years)	48.1 ± 14.6	40.3 ± 12.1	35.4 ± 9.3	<0.01^a
Sex (male/female)	1/30	0/11	1/18	1.00^b
Duration of disease (years)	16.8 ± 11.4	15.8 ± 11.1	―	0.97^c
Average dose of glucocorticoids (mg/day)	6.3 ± 3.5	6.3 ± 4.0	―	0.64^c
Average CRP (mg/dL)	0.43 ± 0.77	0.14 ± 0.21	―	0.052^c
Average ESR (mm/h)	22.6 ± 17.7	20.4 ± 20.9	―	0.69^c
Use of immunosuppressants	8/31 (25.8%)	4/13 (30.8%)	―	0.73^b
Use of biologics	2/31 (6.5%)	0/13 (0%)	―	1.00^b

Values are average ± standard deviation or number of patients. Immunosuppressants: methotrexate (n = 6; n = 4 in the risk group and 2 in the non-risk group) and azathioprine (n = 6; n = 4 in the risk group and 2 in the non-risk group). Biologics: tocilizumab (n = 2)
TAK Takayasu arteritis, CRP C-reactive protein, ESR erythrocyte sedimentation rate
^aStatistical analysis performed by one-way analysis of variance.
^bStatistical analysis performed by Fisher’s exact test
^cStatistical analysis performed by Welch’s t test

ISSN: 1478-6362